Terms: = Colorectal cancer AND IL2, IL-2, 3558, ENSG00000109471, P60568 AND Clinical Outcome
12 results:
1. Treatment of Metastatic or High-Risk Solid cancer Patients by Targeting the Immune System and/or Tumor Burden: Six Cases Reports.
Nicolini A; Ferrari P; Morganti R; Carpi A
Int J Mol Sci; 2019 Nov; 20(23):. PubMed ID: 31795079
[TBL] [Abstract] [Full Text] [Related]
2. Histamine targets myeloid-derived suppressor cells and improves the anti-tumor efficacy of PD-1/PD-L1 checkpoint blockade.
Grauers Wiktorin H; Nilsson MS; Kiffin R; Sander FE; Lenox B; Rydström A; Hellstrand K; Martner A
Cancer Immunol Immunother; 2019 Feb; 68(2):163-174. PubMed ID: 30315349
[TBL] [Abstract] [Full Text] [Related]
3. Potential of memory T cells in bridging preoperative chemoradiation and immunotherapy in rectal cancer.
de Mey S; Jiang H; Wang H; Engels B; Gevaert T; Dufait I; Feron O; Aerts J; Verovski V; De Ridder M
Radiother Oncol; 2018 Jun; 127(3):361-369. PubMed ID: 29871814
[TBL] [Abstract] [Full Text] [Related]
4. CD8
E J; Yan F; Kang Z; Zhu L; Xing J; Yu E
Hum Immunol; 2018 Jun; 79(6):446-452. PubMed ID: 29544815
[TBL] [Abstract] [Full Text] [Related]
5. LAP+CD4+ T cells are suppressors accumulated in the tumor sites and associated with the progression of colorectal cancer.
Mahalingam J; Lin YC; Chiang JM; Su PJ; Fang JH; Chu YY; Huang CT; Chiu CT; Lin CY
Clin Cancer Res; 2012 Oct; 18(19):5224-33. PubMed ID: 22879386
[TBL] [Abstract] [Full Text] [Related]
6. Phase II study of interleukin-2 and 13-cis-retinoic acid as maintenance therapy in metastatic colorectal cancer.
Recchia F; Saggio G; Cesta A; Candeloro G; Di Blasio A; Amiconi G; Lombardo M; Nuzzo A; Lalli A; Alesse E; Necozione S; Rea S
Cancer Immunol Immunother; 2007 May; 56(5):699-708. PubMed ID: 16955297
[TBL] [Abstract] [Full Text] [Related]
7. Chronic immune activation and inflammation in the pathogenesis of AIDS and cancer.
Dalgleish AG; O'Byrne KJ
Adv Cancer Res; 2002; 84():231-76. PubMed ID: 11883529
[TBL] [Abstract] [Full Text] [Related]
8. [Cellular immunotherapy for local recurrence of rectal cancer after surgery by activated lymphocyte administration--a case report].
Sasatomi T; Toh U; Miyagi Y; Ishibashi N; Araki Y; Ogata Y; Yamana H; Shirouzu K
Gan To Kagaku Ryoho; 2001 Oct; 28(11):1692-5. PubMed ID: 11708011
[TBL] [Abstract] [Full Text] [Related]
9. Phase I clinical study applying autologous immunological effector cells transfected with the interleukin-2 gene in patients with metastatic renal cancer, colorectal cancer and lymphoma.
Schmidt-Wolf IG; Finke S; Trojaneck B; Denkena A; Lefterova P; Schwella N; Heuft HG; Prange G; Korte M; Takeya M; Dorbic T; Neubauer A; Wittig B; Huhn D
Br J Cancer; 1999 Nov; 81(6):1009-16. PubMed ID: 10576658
[TBL] [Abstract] [Full Text] [Related]
10. Pre-operative il-2 immunoprophylaxis of cancer recurrence: long-term clinical results of a phase II study in radically operable colorectal cancer.
Brivio F; Lissoni P; Fumagalli L; Girlando M; Marsili MT; Nespoli A; Uggeri F
Oncol Rep; 1999; 6(6):1205-7. PubMed ID: 10523681
[TBL] [Abstract] [Full Text] [Related]
11. The prognostic significance of immune changes in patients with renal cancer, melanoma and colorectal cancer, treated with interferon alpha 2b.
Tsavaris N; Baxevanis C; Kosmidis P; Papamichael M
Cancer Immunol Immunother; 1996 Oct; 43(2):94-102. PubMed ID: 8954143
[TBL] [Abstract] [Full Text] [Related]
12. Biological monitoring of low-dose interleukin 2 in humans: soluble interleukin 2 receptors, cytokines, and cell surface phenotypes.
Hänninen EL; Körfer A; Hadam M; Schneekloth C; Dallmann I; Menzel T; Kirchner H; Poliwoda H; Atzpodien J
Cancer Res; 1991 Dec; 51(23 Pt 1):6312-6. PubMed ID: 1933892
[TBL] [Abstract] [Full Text] [Related]
